BridgeMD
New treatment option for Pulmonary Arterial Hypertension
Official title Exercise-based Rehabilitation in Patients With Pulmonary Arterial Hypertension
ClinicalTrials.gov ID: NCT06804122
What this study is testing
- What it's testing
- Pulmonary arterial hypertension (PAH) is a rare and severe disease characterized by elevation of pulmonary artery pressure (PAP) and increased pulmonary vascular resistance (PVR) due to the narrowing of small pulmonary arteries. The European Society of Cardiology (ESC) and the European Respiratory Society (ERS) recommend supervised exercise-based rehabilitation as part of the treatment of PAH patients alongside optimal medical therapy (Level of evidence A, Class of recommendation I).
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults over 18 years old residing in Tampere or nearby municipalities.
- WHO functional classification II-III.
- Commitment to the exercise program.
- Stable disease condition with no PAH medication changes in the two months prior.
- No recent syncope or arrhythmias causing symptoms within the past two months.
You likely can't join if
- Severe pulmonary disease or left ventricular failure (HFrEF).
- Pregnancy.
- Severe congenital heart defect (Eisenmenger syndrome).
- Severe liver disease.
- Acute inflammatory condition.
- Severe anemia (hemoglobin ≤ 75% of the lower reference limit).
See the full eligibility criteria
- Adults over 18 years old residing in Tampere or nearby municipalities.
- WHO functional classification II-III.
- Commitment to the exercise program.
- Stable disease condition with no PAH medication changes in the two months prior.
- No recent syncope or arrhythmias causing symptoms within the past two months.
- Severe pulmonary disease or left ventricular failure (HFrEF).
- Pregnancy.
- Severe congenital heart defect (Eisenmenger syndrome).
- Severe liver disease.
- Acute inflammatory condition.
- Severe anemia (hemoglobin ≤ 75% of the lower reference limit).
- Systolic blood pressure below 85 mmHg.
- Recent syncope.
- Other significant conditions affecting physical capacity, such as severe neurological diseases or musculoskeletal issues.
- Untreated severe arrhythmias.
- Changes in PAH medication during the rehabilitation program.
The study team makes the final eligibility decision.
Where it's taking place
- Tampere, Pirkanmaa, Finland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tampere, Pirkanmaa, Finland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.